Strong Q4; Gearing Up for U.S. Launch and Continued EU Ramp
Canaccord reiterates “buy” rating and remains bullish on the long-term growth prospects for HeartWare in a global LVAD market.
Canaccord reiterates “buy” rating and remains bullish on the long-term growth prospects for HeartWare in a global LVAD market.